Recombinant human epidermal growth factor

Overview of recombinant human epidermal growth factor

Recombinant Human Epidermal Growth Factor

Classification
External resources

Recombinant human epidermal growth factor (rhEGF) is a synthetic form of the naturally occurring epidermal growth factor (EGF), which is a protein that stimulates cell growth, proliferation, and differentiation by binding to its receptor, EGFR. Recombinant technology allows for the production of EGF in large quantities, which can be used for therapeutic purposes.

Mechanism of Action

Recombinant human epidermal growth factor works by binding to the epidermal growth factor receptor (EGFR) on the surface of cells. This binding activates the receptor's intrinsic tyrosine kinase activity, leading to a cascade of downstream signaling pathways that promote cellular proliferation, differentiation, and survival. These pathways include the MAPK/ERK pathway, the PI3K/AKT pathway, and the JAK/STAT pathway.

Clinical Applications

Recombinant human epidermal growth factor is primarily used in the treatment of chronic wounds, such as diabetic foot ulcers, burns, and other types of skin injuries. It has been shown to accelerate wound healing by promoting the proliferation and migration of keratinocytes and fibroblasts, which are essential for tissue repair.

Diabetic Foot Ulcers

One of the most significant applications of rhEGF is in the treatment of diabetic foot ulcers. These ulcers are a common complication of diabetes mellitus and can lead to severe outcomes, including amputation. rhEGF has been shown to reduce healing time and improve the rate of complete wound closure in patients with diabetic foot ulcers.

Burns

In the context of burn injuries, rhEGF can be applied topically to enhance the healing process. It helps in reducing the time required for re-epithelialization and minimizes the risk of infection and scarring.

Production

Recombinant human epidermal growth factor is produced using recombinant DNA technology. The gene encoding human EGF is inserted into a suitable expression vector, which is then introduced into a host cell, such as Escherichia coli or yeast. The host cells are cultured, and they express the EGF protein, which is then purified for medical use.

Safety and Side Effects

The use of rhEGF is generally considered safe, but it may cause some side effects, including local irritation at the site of application, allergic reactions, and, in rare cases, systemic effects. It is important to monitor patients for any adverse reactions during treatment.

Regulatory Status

Recombinant human epidermal growth factor is approved for use in several countries under various brand names, such as Heberprot-P. Its approval status may vary depending on the specific indication and the regulatory body of the country.

Also see

• Epidermal growth factor receptor
• Growth factors
• Diabetic foot ulcer
• Recombinant DNA technology